ELVNEnliven Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+14% of shares).
Choppy, but holding above its 200-day average. Price is +0% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover. Up 20% since the previous count, up from 11.6% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ELVN is trading
Enliven Therapeutics, Inc. is +91% over the past year while the S&P 500 is +16%: 75 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +0.10%
vs 200-day average · close to trend
- RSI (14)
- 36
RSI (14) · neutral
- Below its 52-week high
- 32%
Below its 52-week high
Details›
- Last close2026-10-23
- $41.50
- 1 monthS&P 500 −0.94%
- −8.0%
- 1 yearS&P 500 +16%
- +91%
- 5 yearsS&P 500 +86%
- +167%
- vs 50-day average$50.19
- −17%
- 52-week high
- $61.15
- 52-week low
- $15.14
- Annualised volatility
- 72%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $52M
| Year | Return |
|---|---|
| 2026 (year to date) | +169% |
| 2025 | −32% |
| 2024 | +63% |
| 2023 | −15% |
| 2022 | +82% |
| 2021 | −90% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | +2.7% |
| Feb | 6 | 4 of 6 | +5.3% |
| Mar | 6 | 4 of 6 | +4.8% |
| Apr | 7 | 2 of 7 | −6.4% |
| May | 7 | 2 of 7 | +14% |
| Jun | 7 | 6 of 7 | +6.9% |
| Jul | 7 | 2 of 7 | −8.2% |
| Aug | 7 | 4 of 7 | −2.0% |
| Sep | 7 | 3 of 7 | +7.2% |
| Oct | 7 | 3 of 7 | +9.4% |
| Nov | 6 | 1 of 6 | +3.6% |
| Dec | 6 | 1 of 6 | −11% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.